Therapeutic EUS is a growing and exciting field that is advancing endoscopic treatments for patients with complex pancreaticobiliary diseases. Learn more about the AXIOS™ Stent and Delivery System below.*
AXIOS System In-Service Videos
Dr. Baron takes an in-depth look at the AXIOS Platform, sharing procedural tips and techniques, different methods and imaging modalities.
AXIOS System Webcast Series
Watch this webcast presented by Martin L. Freeman M.D., FACG, FASGE; Professor of Medicine, Chief, Division of Gastroenterology, at the University of Minnesota.
Dr. Kowalski discusses patient selection criteria and the characteristics of pancreatic fluid collections (PFCs) to determine when to provide therapeutic intervention.
Watch this webcast presented by Amrita Sethi MD where she discusses tips and techniques for success in using the AXIOS System
Watch this webcast presented by Todd Baron M.D. on his options and techniques for after AXIOS™ Stent placement.
Hear Dr. Varadarajulu’s opinions on necrosectomy techniques and other considerations for AXIOSTM Stent post-placement.
Janak Shah, MD and Charles Conway, MD discuss the multidisciplinary management of inflammatory pancreatic fluid collections.
*The AXIOS™ Stent and Electrocautery-Enhanced Delivery System Indications for Use:
• US: The AXIOS Stent and Electrocautery-Enhanced Delivery System is indicated for use to facilitate transgastric or transduodenal endoscopic drainage of symptomatic pancreatic pseudocysts 6cm in size, with >70% fluid content that are adherent to the gastric or bowel wall. Once place, the AXIOS Stent functions as an access port allowing passage of standard and therapeutic endoscopes to facilitate debridement, irrigation and cystoscopy. The stent is intended for implantation up to 60 days and should be removed upon confirmation of pseudocyst resolution.
• Europe: The Hot AXIOS Stent and Electrocautery Enhanced Delivery System is indicated for use to facilitate transgastric or transduodenal endoscopic drainage of a pancreatic pseudocyst, walled-off necrosis (>70% fluid content) or the biliary tract.